Mammary Cell News 9.38 September 28, 2017 | |
| |
TOP STORYMYC Inhibition Depletes Cancer Stem-Like Cells in Triple-Negative Breast Cancer Researchers report that Triptolide (C1572), a small molecule natural product selectively depletes cancer stem-like cells in a dose-dependent fashion in human triple-negative breast cancer cell lines. Nanomolar concentrations of C1572 markedly reduced c-MYC (MYC) protein levels via a proteasome-dependent mechanism. [Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists used deficiency in the mitochondrial enzyme cytochrome c oxidase (CCO), typically caused by somatic mutations in the mitochondrial genome, as a means to perform lineage tracing in the human mammary epithelium. The presence of a stem cell population was shown by demonstrating multilineage differentiation within CCO-deficient areas. [J Pathol] Abstract Epithelial Vimentin Plays a Functional Role in Mammary Gland Development Investigators studied how vimentin deficiency affected mouse mammary gland development. They found that in adult vimentin knockout mice (Vim-/-) mammary ductal outgrowth is delayed. The adult Vim-/- glands display dilated ducts and reduced basal to luminal mouse mammary epithelial cell ratio indicative of altered progenitor cell activity. [Development] Abstract The authors investigated miR-101 expression in breast cancer (BC) tissues and investigated its roles in BC progression that were mediated by Sex-determining region Y-box 2 (SOX2), a critical oncogene in various cancers. SOX2 knockdown mimicked the effects of miR-101 overexpression on the malignant behaviors of BC cells, while SOX2 overexpression mitigated the miR-101-induced inhibition of these effects. [Cell Physiol Biochem] Full Article TNFα-YAP/p65-HK2 Axis Mediates Breast Cancer Cell Migration Scientists showed that yes-associated protein 1 (YAP1), a transcriptional regulator that controls tissue growth and regeneration, has an important role in tumor necrosis factor α (TNF α)-induced breast cancer migration. Chromatin immunoprecipitation assay showed that YAP/TEAD (TEA domain family member) and p65 proteins synergistically regulated the transcription of hexokinase 2 (HK2), a speed-limiting enzyme in glycolysis, and promoted TNFα-induced or macrophage conditioned medium-induced cell migration. [Oncogenesis] Full Article Morphomechanical and Structural Changes Induced by ROCK Inhibitor in Breast Cancer Cells RHO family regulates the activation or suppression of Rho-associated coiled-coil containing protein kinase (ROCK) which in turn regulates the cytoskeleton dynamics. Researchers used a strong ROCK inhibitor, Y-27632, to evaluate the effects of inhibition on living breast cancer epithelial cells by a biomechanical approach. [Exp Cell Res] Abstract | Graphical Abstract Expression of aldehyde dehydrogenase (ALDH)1A1 or ALDH1A3 was knocked down in MDA-MB-468 and SUM159 human breast cancer cells using siRNA. Resulting impacts on ALDH activity, metastatic behavior and therapy response in vitro and extravasation/metastasis in vivo was assessed. [Int J Mol Sci] Full Article Researchers investigated the effect of increasing concentrations of zoledronic acid in breast cancer cell lines in the absence or presence of estradiol to mimic the hormonal environment in vitro. [PLoS One] Full Article Taxol Reduces Synergistic, Mechanobiological Invasiveness of Metastatic Cells It has been shown that the mechanobiological invasiveness of metastatic cells can be determined through their mechanical interactions with a synthetic polyacrylamide gel; metastatic cells indent gels in attempted invasion, while benign cells do not. [Converg Sci Phys Oncol] Abstract | Full Article | |
| |
REVIEWSFatty Acid Synthase (FASN) as a Therapeutic Target in Breast Cancer The authors review the preclinical lessons learned from the pharmaceutical liabilities of the first generation of FASN inhibitors. They provide an updated view of the current development and clinical testing of next generation FASN-targeted drugs. [Expert Opin Ther Targets] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSInfinity Pharmaceuticals, Inc. announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb evaluating IPI-549 in combination with Opdivo® to include patients with triple negative breast cancer who have not been previously exposed to anti-PD-1 or anti-PD-L1 therapy. [Infinity Pharmaceuticals, Inc. (PR Newswire Association LLC.)] Press Release Susan G. Komen announced 2017 research funding of $30.7 million for 98 research grants, with a focus on new treatments and understanding of the most lethal forms and stages of breast cancer. [Susan G Komen] Press Release UW Carbone Center Researcher Receives Komen Grant A UW-Madison researcher has received a grant from the Susan G. Komen Foundation, the world’s leading breast-cancer organization. Dr. Eui-Jun Kim, a post-doctoral researcher at UW Carbone Cancer Center and McArdle Laboratory for Cancer Research, will receive $185,000 for a study of triple-negative breast cancer. [University of Wisconsin School of Medicine and Public Health] Press Release SYNERGYS Announces Phase I SBIR Grant Award From National Institutes of Health Synergys Biotherapeutics announced the receipt of a Phase I grant from the National Cancer Institute under auspices of the Small Business Innovation Research program of the National Institutes of Health. The grant will be utilized for the development of SYN001, an antibody fusion molecule containing an anti-EGFR antibody incorporating a highly anti-angiogenic dimeric mutant endostatin as its fusion partner. [Synergys Biotherapeutics (Business Wire, Inc.)] Press Release Galena Biopharma, Inc. announced that two clinical trials evaluating NeuVax™ (nelipepimut-S) in combination with trastuzumab (Herceptin®; Genentech/Roche) for the prevention of recurrence in breast cancer patients have enrolled the protocol-defined number of patients to complete enrollment. The milestones were reported by the clinical research organization conducting both trials – a Phase IIb clinical trial in HER2 1+/2+ patients and a Phase II clinical trial in HER2 3+ patients. [Galena Biopharma, Inc.] Press Release | |
| |
POLICY NEWSHow the Latest US Travel Ban Could Affect Science Trump announced permanent travel restrictions on citizens of Chad, Iran, Libya, North Korea, Somalia, Syria, Venezuela and Yemen. That list includes five Muslim-majority countries that were targeted in the White House’s first and second travel bans, which Trump signed in January and March. Those policies, which were designed as temporary measures, have been limited by a series of federal court rulings. [Nature News] Editorial Researchers Caught in Growing Rift over Catalan Independence Researchers have much at stake in the independence referendum, in defiance of Madrid’s central government. Nationalists trust that Catalan science would thrive in a nimbler, independent state of 7.5 million people and become a beacon of a new, progressive republic. Others fear that the secession would plunge science into isolating uncertainty, cut access to essential funding streams and networks, and spark a brain drain. [ScienceInsider] Editorial Canada Names New Chief Science Adviser Mona Nemer, a cardiology researcher and vice-president of research at the University of Ottawa, has been named Canada’s new Chief Science Adviser by Prime Minister Justin Trudeau. [ScienceInsider] Editorial What Germany’s Election Results Mean for Science As Germany reels from an unexpected surge for the far right in the elections, researchers don’t expect much effect on the country’s generous support for science. But with smaller parties standing to gain political influence, battles over issues such as the regulation of gene-edited organisms and how to cut greenhouse-gas emissions could grow fiercer. [Nature News] Editorial
| |
EVENTSNEW The 2018 World Stem Cell Summit (WSCS) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel) Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Opportunities – Cancer Research (Albert Einstein College of Medicine in New York) Postdoctoral Position – Mammary Gland Stem Cells (Université Libre de Bruxelles) Postdoctoral Position – Mammary Tumors (Cancer Research UK Beatson Institute) Clinician Investigator – Breast Cancer Research (Mayo Clinic) Research Fellows – Cancer Research (National University of Singapore) Multiple Positions – Cancer Research (National University of Singapore) Associate Medical Director/Medical Director – Breast Cancer (Genentech, Inc.) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|